VivoSim Labs has recently expanded its presence in the Asian market through strategic distributor partnerships in Korea and China. The company has appointed JCBio and Tekon Biotech as its official distributors in these regions.
Enhanced Market Access in Asia
This move aims to facilitate the adoption of VivoSim Labs’ advanced New Approach Methodologies (NAMs) for preclinical safety screening. By leveraging the local expertise and networks of JCBio and Tekon Biotech, VivoSim Labs is positioning its innovative solutions to better serve customers in the Korean and Chinese markets.
Benefits of the New Distributor Partnerships
- Improved availability of cutting-edge preclinical safety screening technologies.
- Increased support and service for clients through local partners.
- Acceleration of regulatory acceptance of New Approach Methodologies in Asia.
Through these collaborations, VivoSim Labs is committed to advancing safer and more efficient drug development practices across key Asian markets.
About The Author
